Vaccinations against preventable diseases, including seasonal influenza, are strongly recommended for patients with rheumatoid arthritis (RA), who are at increased risk of infections as a result of underlying immune dysfunction and treatment-induced immunosuppression. Park et al. conducted this clinical trial to investigate whether discontinuing methotrexate for one week after seasonal influenza vaccination is noninferior to discontinuing it for two weeks after vaccination in patients with RA. ... [Read More]
Search results for: methotrexate
Insights into Methotrexate Toxicity in Elderly Patients with Rheumatic Disease
Data from a small study show that severe methotrexate toxicity in patients who are 70 years of age and older and have rheumatic disease may be associated with poor renal function and the use of diuretic treatments.... [Read More]
Study: Pegloticase & Methotrexate Co-Treatment Helps Uncontrolled Gout
A larger proportion of patients with gout had a therapeutic response at six months when treated with methotrexate and pegloticase than with pegloticase alone, according to results from the multi-center, open-label MIRROR (methotrexate to increase response rates in patients with uncontrolled gout receiving KRYSTEXXA) study, recently published in the Journal of Rheumatology.1 The MIRROR study… [Read More]
Maxed Out Methotrexate?
Upadacitnib for RA: Researchers Compared Upadacitinib with Placebo & Adalimumab in Patients with RA & an Inadequate Response to Methotrexate
In phase 3 clinical trial, upadacitnib proved superior to placebo and adalimumab in improving the signs and symptoms of RA in patients on stable background methotrexate.... [Read More]
Pulmonary Adverse Events with Low-Dose Methotrexate
In this large placebo-controlled trial, Sparks et al. examined the predictors and severity of pulmonary adverse events (AEs) in patients taking low-dose MTX. The researchers found that low-dose MTX increased the risk of pulmonary AEs, including possible pneumonitis.... [Read More]
The Great Debate: Should Jakinibs Be Used Before Biologics after Methotrexate Failure in RA?
ACR CONVERGENCE 2020—In many ways, the current plethora of treatment options for rheumatoid arthritis patients represents an embarrassment of riches. However, while many therapeutics approved by the U.S. Food & Drug Administration (FDA) are available, knowing the order in which to try these medications with patients can be quite challenging. In The Great Debate, held… [Read More]
Low-Dose Methotrexate Can Cause Adverse Effects
NEW YORK (Reuters Health)—Low-dose methotrexate can be associated with gastrointestinal, pulmonary, infectious, hematologic and other adverse effects, according to an analysis of the Cardiovascular Inflammation Reduction Trial (CIRT). “Methotrexate is not a benign drug, even at dosages used for rheumatic diseases,” Daniel H. Solomon, MD, MPH of Brigham and Women’s Hospital, Boston, tells Reuters Health… [Read More]
Pegloticase & Methotrexate Combination Therapy May Benefit Patients with Uncontrolled Gout
Patients with uncontrolled gout may benefit from a combination of pegloticase and methotrexate therapy, according to a small, retrospective study…... [Read More]
Case Report: RA Patient Suffers Methotrexate-Induced Cutaneous Lesions
Methotrexate (MTX) remains the predominant medication used by rheumatologists to treat rheumatoid arthritis (RA). Doses of 7.5–25 mg per week with daily folic acid are generally prescribed. Despite its common use, MTX must be prescribed cautiously given the potential adverse effects when taken incorrectly or without folic acid supplementation. Cases of MTX-induced cutaneous ulceration have… [Read More]
- 1
- 2
- 3
- …
- 96
- Next Page »